GlassScriptPhysician profile
Sarah J Levan
NPI 1720152911
$6,438.72
in general payments reported to CMS, 2019-2025
44 companies · $1,455 in 2025
The $1,455 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $844 · 2022: $1,217 · 2023: $1,398 · 2024: $1,525 · 2025: $1,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,377.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $952.21 | 2021-2025 | |
| Novo Nordisk INC | $841.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $613.32 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $387.91 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.99 | 2021-2025 | Xifaxan |
| Abbott Laboratories | $252.20 | 2021-2025 | Freestyle Libre 3, Eterna |
| Astrazeneca Pharmaceuticals LP | $229.94 | 2023-2025 | Airsupra, Enhertu, Farxiga |
| Lilly USA, LLC | $228.05 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $199.96 | 2021-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.08 | 2021-2025 | Jardiance, Ofev |
| E.R. Squibb & Sons, L.L.C. | $172.43 | 2021-2024 | Eliquis, Camzyos |
| Dexcom, INC. | $165.66 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $164.33 | 2021-2025 | |
| Amgen INC. | $156.07 | 2023-2024 | Repatha, Otezla, Evenity |
| Xeris Pharmaceuticals, INC. | $139.83 | 2023-2025 | Gvoke Hypopen |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Levan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.